Stoke Therapeutics Inc (STOK): Company Current Liabilities

Graphic logo of Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics (STOK) develops RNA-based drugs for the treatment of CNS and kidney pathologies, ensuring a steady revenue stream due to patients' lifelong need for therapy. This price chart illustrates the asset's dynamics, with the current indicator standing at 0.00. The business relies on US gene function restoration centers, while its humanitarian operational profile shields the company from sanctions and geopolitical risks.

STOK Stoke Therapeutics, Inc. Short-Term Debt (07/04/2022 - 10/30/2026)

Analytical breakdowns and data insights for company Stoke Corp (STOK)

- current quotes and average value forecast:
Price Chart Stoke Therapeutics, Inc.|STOK - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Stoke Therapeutics, Inc.|STOK - Aggregate Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Stoke Therapeutics|STOK - Total Stockholders' Equity|Market Value to Book Value Ratio stoketherapeutics.com|STOK - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Stoke Therapeutics|STOK - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Stoke Therapeutics|STOK - Aggregate Debt Obligations|Debt to Book Value Stoke Therapeutics, Inc.|STOK - Amount of Long-Term Liabilities|Company Short-Term Debts Stoke Therapeutics|Quick Ratio stoketherapeutics.com
- earnings and multiples data:
STOK - Company Net Income
General company analysis:Stoke Therapeutics, Inc. - STOK
Manufactured products of stoketherapeutics.com

Short-term debt aggregates all company obligations due within the next year, including loans and notes. This metric determines the issuer's current solvency and liquidity risk. By analyzing the short-term debt trend, an investor assesses the stability of financial leverage. For Stoke Therapeutics (STOK), this indicator is critical when financing costly RNA developments. Debt control ensures the uninterrupted creation of drugs for the therapy of Dravet syndrome.

Who Stoke Therapeutics competes with

TEM - Company Short-Term Debt|Short-Term Debt Volume Qiagen NV QGEN|IONS (Ionis Pharma) - Company Current Liabilities|RGEN: Amount of Current Liabilities|Company Short-Term Debt Avidity Biosciences|Short-Term Debt crisprtx.com CRSP|Company Short-Term Debt GeneDx (WGS)|Company Short-Term Debts Ultragenyx Pharmaceutical Inc. (RARE)|Company Short-Term Debts BEAM (Beam Therapeutics Corp)|Sarepta Corp (SRPT) - Short-Term Debt|TWST: Company Current Liabilities|Company Short-Term Loans and Borrowings TXG (10xgenomics.com)|NTLA (Intellia Therapeutics, Inc.) - Company Current Liabilities|BLFS: Amount of Current Liabilities|WVE (Wave Life Sciences Corp) - Company Short-Term Debts|MAZE: Company Short-Term Loans and Borrowings|Company Short-Term Debts SION|PRME - Short-Term Debt|Company Short-Term Debt Taysha Gene Therapies, Inc. TSHA|Company Short-Term Loans and Borrowings QURE|MeiraGTx PLC - Company Short-Term Debts|RGNX - Company Short-Term Debts|Solid Biosciences Inc. (SLDB) - Company Short-Term Debt|Current Liabilities OCGN (ocugen.com)|PACB (PacBio) - Company Short-Term Debts|Short-Term Debt Benitec Biopharma Inc BNTC|Company Current Liabilities DSGN (Design Pharma)|Company Short-Term Debts Rocket Corp (RCKT)|4D Molecular Therapeutics - Company Current Liabilities|Amount of Current Liabilities LXEO (Lexeo Therapeutics Inc.)|Korro Bio, Inc - Company Short-Term Debts|Short-Term Debt Volume Editas Medicine Inc EDIT|SLN: Company Short-Term Debts|Company Current Liabilities ProQR Therapeutics|Company Short-Term Debt Codexis Inc|sangamo.com (SGMO) - Short-Term Debt Volume|Company Short-Term Debt Nautilus Biotechnology (NAUT)|Short-Term Debt Volume Metagenomi Inc.|Precision BioSciences - Company Current Liabilities|Amount of Current Liabilities GBIO (Generation Bio Co)|BOLD - Company Short-Term Debt|Short-Term Debt Exicure, Inc.|imunon.com (IMNN) - Company Short-Term Debt|Phio Pharmaceuticals Corp. (PHIO) - Company Short-Term Debts|MBIO (Mustang Bio Inc) - Company Short-Term Debts|Company Short-Term Indebtedness RNAZ (TransCode)|Company Short-Term Debt Bionano Genomics, Inc. (BNGO)|adnas.com - Company Short-Term Indebtedness|Company Short-Term Debts BLUE (bluebird bio)|Company Short-Term Debts ImmunoPrecise Antibodies Ltd IPA|OMGA - Company Short-Term Debt|Short-Term Debt Volume Singular Genomics Corp OMIC|RGLS (Regulus Therapeutics) - Company Current Liabilities|SYRS: Amount of Current Liabilities|Company Short-Term Debt Telesis Bio|Short-Term Debt TRACON Pharmaceuticals Inc. TCON|Company Short-Term Debt Unity Bio (UBX)